AU2001290841A1 - Water soluble rapamycin esters - Google Patents

Water soluble rapamycin esters

Info

Publication number
AU2001290841A1
AU2001290841A1 AU2001290841A AU9084101A AU2001290841A1 AU 2001290841 A1 AU2001290841 A1 AU 2001290841A1 AU 2001290841 A AU2001290841 A AU 2001290841A AU 9084101 A AU9084101 A AU 9084101A AU 2001290841 A1 AU2001290841 A1 AU 2001290841A1
Authority
AU
Australia
Prior art keywords
water soluble
soluble rapamycin
rapamycin esters
esters
hydroxyesters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001290841A
Inventor
Mahdi Bakir Fawzi
Tianmin Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of AU2001290841A1 publication Critical patent/AU2001290841A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

This invention provide pegylated hydroxyesters of rapamycin which are useful in inducing immunosuppression and in the treatment of transplantation rejection, autoimmune diseases, solid tumors, fungal infections, and vascular disease.
AU2001290841A 2000-09-19 2001-09-13 Water soluble rapamycin esters Abandoned AU2001290841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23377600P 2000-09-19 2000-09-19
US60/233,776 2000-09-19
PCT/US2001/028575 WO2002024706A2 (en) 2000-09-19 2001-09-13 Water soluble rapamycin esters

Publications (1)

Publication Number Publication Date
AU2001290841A1 true AU2001290841A1 (en) 2002-04-02

Family

ID=22878646

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001290841A Abandoned AU2001290841A1 (en) 2000-09-19 2001-09-13 Water soluble rapamycin esters

Country Status (13)

Country Link
US (1) US6432973B1 (en)
EP (1) EP1319008B1 (en)
JP (1) JP2004509898A (en)
CN (1) CN1222529C (en)
AT (1) ATE411321T1 (en)
AU (1) AU2001290841A1 (en)
BR (1) BR0113975A (en)
CA (1) CA2421485A1 (en)
DE (1) DE60136200D1 (en)
DK (1) DK1319008T3 (en)
ES (1) ES2313983T3 (en)
MX (1) MXPA03002258A (en)
WO (1) WO2002024706A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250135B1 (en) 2000-01-14 2010-07-28 The Trustees of The University of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1389209B1 (en) 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
EA008379B1 (en) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Phosphorus-containing compounds & uses thereof
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
ATE385795T1 (en) * 2002-07-30 2008-03-15 Wyeth Corp PARENTERAL FORMULATIONS CONTAINING A RAPAMYCIN HYDROXYESTER
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
NZ541846A (en) 2003-01-27 2008-12-24 Endocyte Inc Vitamin receptor binding drug delivery conjugates
US20040213757A1 (en) * 2003-04-23 2004-10-28 Wyeth Holdings Corporation Water soluble wortmannin derivatives
AR046194A1 (en) * 2003-11-04 2005-11-30 Mayo Foundation TREATMENT METHOD OF MANTO CELL LYMPHOMA
JP2007512369A (en) * 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド Treatment of rheumatoid arthritis with hypoxia-inducible factor 1α antagonist
AR047988A1 (en) * 2004-03-11 2006-03-15 Wyeth Corp ANTI -OPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB
CA2562952A1 (en) 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
MXPA06012404A (en) * 2004-04-27 2007-01-17 Wyeth Corp Labeling of rapamycin using rapamycin-specific methylases.
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
MX2007010892A (en) * 2005-03-07 2007-12-05 Wyeth Corp Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin.
EP1863816B1 (en) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
EP2382995A3 (en) * 2005-08-19 2013-09-25 Endocyte, Inc. Ligand conjugates of Vinca alkaloids, analogs and derivatives
ES2468240T3 (en) * 2005-08-19 2014-06-16 Endocyte, Inc. Multiple drug ligand conjugates
CN101351702A (en) * 2005-12-07 2009-01-21 惠氏公司 Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
JP2009518413A (en) 2005-12-07 2009-05-07 ワイス Process for preparing purified crystalline CCI-779
RU2008120670A (en) * 2005-12-07 2010-01-20 Вайет (Us) SCALABLE METHOD FOR PRODUCING 42-COMPOUND ETHER OF RAPAMYCIN FROM 42-COMPOUND ETHER OF RAPAMYCIN BORONATE
KR20080106225A (en) * 2006-03-07 2008-12-04 와이어쓰 Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants
US20080207671A1 (en) * 2006-07-31 2008-08-28 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
TW200824713A (en) 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008094181A2 (en) * 2007-02-01 2008-08-07 The Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
US20100104626A1 (en) * 2007-02-16 2010-04-29 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CA2680535C (en) * 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
CN101676291B (en) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 Rapamycin carbonate analog, pharmaceutical composition thereof, and preparation method and uses thereof
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
MX2015004757A (en) 2012-10-16 2015-07-17 Endocyte Inc Drug delivery conjugates containing unnatural amino acids and methods for using.
JP6770008B2 (en) 2016-05-10 2020-10-14 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． Water-soluble rapamycin derivative
WO2019184993A1 (en) * 2018-03-29 2019-10-03 天津键凯科技有限公司 Combination of polyethylene glycol and rapamycin and use thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US4375464A (en) 1981-11-19 1983-03-01 Ayerst, Mckenna & Harrison Inc. Antibiotic AY24,668 and process of preparation
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
JP2631710B2 (en) 1988-08-16 1997-07-16 日本ヘキスト・マリオン・ルセル株式会社 Pyrano [f] quinolinone derivative and pharmaceutical composition containing the compound as an active ingredient
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
PT98990A (en) * 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5130307A (en) * 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5093338A (en) 1991-04-23 1992-03-03 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5102876A (en) 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
ATE135583T1 (en) 1991-06-18 1996-04-15 American Home Prod USE OF RAPAMYCIN TO TREAT T-CELL LYMPHOMA/LEUKEMIA IN ADULTS
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Pharmaceutical compositions for treating ocular inflammation comprising rapamycin
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
ES2148224T3 (en) 1992-03-30 2000-10-16 American Home Prod RAPAMICINE FORMULATION FOR INTRAVENOUS INJECTIONS.
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
AU6711994A (en) * 1993-04-23 1994-11-21 American Home Products Corporation Rapamycin conjugates and antibodies
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral rapamycin formulations
US5516770A (en) 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration

Also Published As

Publication number Publication date
EP1319008B1 (en) 2008-10-15
DK1319008T3 (en) 2009-02-09
BR0113975A (en) 2003-07-29
ES2313983T3 (en) 2009-03-16
MXPA03002258A (en) 2003-06-24
CN1460108A (en) 2003-12-03
CA2421485A1 (en) 2002-03-28
EP1319008A2 (en) 2003-06-18
CN1222529C (en) 2005-10-12
US6432973B1 (en) 2002-08-13
ATE411321T1 (en) 2008-10-15
JP2004509898A (en) 2004-04-02
WO2002024706A3 (en) 2002-10-10
US20020055518A1 (en) 2002-05-09
WO2002024706A2 (en) 2002-03-28
DE60136200D1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
AU2001290841A1 (en) Water soluble rapamycin esters
WO2002028866A3 (en) Hydroxyesters of 7-desmethylrapamycin
WO2002028867A3 (en) Ethers of 7-desmethylrapamycin for use in immunosuppression
WO2002026746A3 (en) 1-oxorapamycins
MXPA04001524A (en) Rapamycin 29-enols.
MXPA04001523A (en) Rapamycin dialdehydes.
WO2003074551A3 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
ATE349976T1 (en) MICROSTRUCTURE STENT STRUCTURE
ES2115255T3 (en) DERIVATIVES OF RAPAMICINA WITH THE RING STABILIZED IN C-22.
CA2530421A1 (en) Repair and regeneration of ocular tissue using postpartum-derived cells
SI1546088T1 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
EP1751272B8 (en) Production of tacrolimus (fk-506) using new streptomyces species
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2004091436A3 (en) Methods and compositions for treating ocular disease
HK1071079A1 (en) Use of soluble fgl2 as an immunosuppressant
WO2005009333A3 (en) Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
WO2002006303A3 (en) Dna vaccines encoding hiv accessory proteins
WO2001045680A3 (en) Cd45 inhibitors
WO2001017536A3 (en) Novel autogenous vaccines used to obtain an immune tolerance
AU2002348160A1 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
WO2000078329A3 (en) The use of the protein uk 114 for inhibiting organ transplant rejection
WO2004069142A8 (en) Anti-candida agents for the treatment of prion diseases
WO2002047697A3 (en) Fractions of snake blood, their preparation and use as therapeutic agents
RU2005111870A (en) PEPTID POSSESSING ANTICOAGULANT, FIBRINDEPOLIMERIZATION, ANTITROMBOTIC AND FIBRINOLYTIC ACTIVITY